Tempus AI has received FDA 510(k) clearance for ECG-PH, artificial-intelligence software that analyzes routine 12-lead electrocardiograms for signs associated with elevated pulmonary artery pressure in symptomatic adults without a known pulmonary-hypertension diagnosis.
Tempus ECG-PH analyzes routine 12-lead ECGs from symptomatic adults aged 40 and older and returns a binary signal associated with elevated pulmonary artery pressure, but it is not a stand-alone diagnosis.
Tempus AI’s PRISM2 foundation model matched or exceeded specialised pathology products across several retrospective cancer-detection tests while also supporting biomarker and survival predictions. The results strengthen the case for general-purpose pathology artificial intelligence, but PRISM2 is not yet an FDA-authorised diagnostic device.
Median Technologies and Olea Medical will deploy eyonis LCS across United States and European lung cancer screening workflows.
Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.
Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.
Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.